1. Introduction {#sec1-cancers-11-00775}
===============

The high frequency of genomic alterations in lymphomas affecting genes coding for proteins involved in the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway \[[@B1-cancers-11-00775],[@B2-cancers-11-00775]\] highlights the importance of this signaling cascade as a therapeutic target. mTOR is an atypical serine/threonine kinase that mediates a variety of signals that directly or indirectly regulate cellular growth and metabolism \[[@B3-cancers-11-00775],[@B4-cancers-11-00775]\]. It is present in two complexes, mTOR complex 1 (TORC1) and mTOR complex 2 (TORC2), which differ for the presence of additional proteins. Acute exposure to rapamycin inhibits TORC1 but not TORC2. It is now recognized that not only TORC1 but also TORC2 is positively regulated by the PI3K signaling \[[@B3-cancers-11-00775],[@B4-cancers-11-00775]\]. Importantly, the first generation of mTOR inhibitors, sirolimus (rapamycin), temsirolimus (CCI779), everolimus (RAD001) and ridaforolimus (AP23573/MK-8669), act as allosteric inhibitors blocking the interaction between mTOR and FBPK12 resulting in inhibition of TORC1 only \[[@B3-cancers-11-00775],[@B4-cancers-11-00775]\]. These compounds are also known as rapalogs since they are chemically derived from rapamycin and maintain the same mechanism of action \[[@B3-cancers-11-00775],[@B4-cancers-11-00775]\]. Rapalogs have shown preclinical and clinical anti-lymphoma activity \[[@B3-cancers-11-00775],[@B4-cancers-11-00775],[@B5-cancers-11-00775],[@B6-cancers-11-00775]\]. In particular, temsirolimus demonstrated a higher response rate and progression free survival than investigators' treatment choices in relapsed or refractory mantle cell lymphoma \[[@B7-cancers-11-00775],[@B8-cancers-11-00775]\] and was approved by the European Medicines Agency (EMA) for patient populations \[[@B6-cancers-11-00775]\]. However, the clinical activity of first generation mTOR inhibitors remains relatively limited and their use comes with side effects, as also demonstrated in two recently reported phase III clinical trials. The result of Temsirolimus was that it was less active and more toxic than the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib \[[@B9-cancers-11-00775]\] and the addition of everolimus after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) did not improve the outcome of patients with newly diagnosed high-risk diffuse large B cell lymphoma (DLBCL) \[[@B10-cancers-11-00775]\]. Biologically, the inability of rapalogs to inhibit TORC1 associated with the activation of pro-survival feedback loops are known limitations in the mechanism of action of these types of compounds \[[@B3-cancers-11-00775],[@B4-cancers-11-00775]\]. One way to overcome these problems is the design of dual TORC1/2 inhibitors that target the catalytic site of mTOR \[[@B3-cancers-11-00775],[@B4-cancers-11-00775],[@B11-cancers-11-00775],[@B12-cancers-11-00775],[@B13-cancers-11-00775]\], thus blocking the enzyme independently from its interacting proteins. Second generation mTOR inhibitors have shown stronger preclinical anti-tumor activity than allosteric mTOR inhibitors \[[@B3-cancers-11-00775],[@B4-cancers-11-00775],[@B11-cancers-11-00775],[@B12-cancers-11-00775],[@B13-cancers-11-00775],[@B14-cancers-11-00775],[@B15-cancers-11-00775]\]. Results of the first reported phase I studies support this approach \[[@B3-cancers-11-00775],[@B4-cancers-11-00775],[@B16-cancers-11-00775],[@B17-cancers-11-00775],[@B18-cancers-11-00775]\], although the toxicity profile can still represent an important issue \[[@B19-cancers-11-00775],[@B20-cancers-11-00775]\]. Here, we report the anti-tumor activity of the brain penetrant dual TORC1/2 inhibitor PQR620 \[[@B13-cancers-11-00775]\] as a single agent and in combination with venetoclax in lymphoma models.

2. Results {#sec2-cancers-11-00775}
==========

2.1. PQR620 Has In Vitro Anti-Lymphoma Activity {#sec2dot1-cancers-11-00775}
-----------------------------------------------

The anti-tumor activity of the novel TORC1/2 inhibitor PQR620 was assessed in a large panel of cell lines (*n* = 56) derived from lymphomas. The compound showed potent anti-proliferative activity in most of the tested cell lines ([Table 1](#cancers-11-00775-t001){ref-type="table"}), with a median IC~50~ of 249.53 nM (95% C.I., 221--294). The most sensitive subtype was mantle cell lymphoma (MCL) (*p* = 0.0232 among all human cell lines; *p* = 0.0552 within B-cell lymphomas) ([Table 2](#cancers-11-00775-t002){ref-type="table"}). Conversely, the ALK+ anaplastic large cell lymphomas (ALK+ALCL) were the least sensitive (*p* = 0.0095) ([Table 2](#cancers-11-00775-t002){ref-type="table"}). When we focused on diffuse large B cell lymphomas (DLBCL), representing the largest group of cell lines, the presence of *MYC* or *BCL2* or the cell of origin did not affect the response to PQR620. However, DLBCL cell lines bearing *TP53* inactivation were less sensitive than *TP53* wild-type cells (300 nM (95% C.I., 242--364) vs. 136 nM (95% C.I., 74--233); *p* = 0.0007). The anti-tumor activity of PQR620 appeared mostly cytostatic. Apoptosis induction was only seen in 8/56 cell lines (14%: 95% C.I., 6--26%) without association with histotype, *BCL2*, *MYC* or *TP53* status ([Table 1](#cancers-11-00775-t001){ref-type="table"}). PQR620 was able to act both on the TORC1 and TORC2 pathways. Immunoblotting of DLBCL cell lines exposed to PQR620 (2 µM, 24 h) showed reduction of p-p70 S6 (Thr389) and p-4e-BP1 (Thr37/46) levels, indicative of TORC1 inhibition, and of p-AKT (Ser 473), indicative of TORC2 inhibition ([Figure 1](#cancers-11-00775-f001){ref-type="fig"}).

2.2. PQR620 Has In Vivo Anti-Lymphoma Activity {#sec2dot2-cancers-11-00775}
----------------------------------------------

The observed in vitro anti-tumor activity of PQR620 was then evaluated in an in vivo model using the activated B-cell-like (ABC) DLBCL RI-1 cell line. Treatments with PQR620 (100 mg/kg dose per day, one a day for 7 days/week (Qdx7/w)) started with 100--150 mm^3^ tumors and were carried out for 21 days. PQR620 determined a decrease of the tumor volumes in comparison with controls from day 12 (*p* \< 0.05) ([Figure 2](#cancers-11-00775-f002){ref-type="fig"}). There was no toxicity observed (reported as body weight loss).

2.3. PQR620 Has In Vitro and In Vivo Synergism with the BCL2 Inhibitor Venetoclax {#sec2dot3-cancers-11-00775}
---------------------------------------------------------------------------------

Due to the low induction of apoptosis after PQR620 as a single agent, we assessed the combination of the dual TORC1/2 inhibitor and the BCL2 inhibitor venetoclax in four DLBCL cell lines. The combination was in vitro synergistic in terms of anti-proliferative effect, as shown by exposing the cell lines to increasing doses of PQR620 and venetoclax as single agents or in combination ([Figure S1](#app1-cancers-11-00775){ref-type="app"}). The addition of venetoclax increased the cell death, as indicated by a higher percentage of cells in the subG0 phase, in all the cell lines but the RI-1 in which the BCL2-inhibitor as a single agent was already highly cytotoxic ([Figure 3](#cancers-11-00775-f003){ref-type="fig"}).

Based on the in vitro data, the activity of PQR620 (100 mg/kg dose per day, Qdx7/w, 21 days) in combination with venetoclax (100 mg/kg, Qdx7/w) was evaluated in an in vivo model using the germinal center B-cell type (GCB)-DLBCL cell line SU-DHL-6, bearing the t(14;18) chromosomal translocation ([Figure 4](#cancers-11-00775-f004){ref-type="fig"}). PQR620 determined a 2-fold decrease of the tumor volumes in comparison with controls. The combination of PQR620 with venetoclax showed highly significant differences either versus control or single agents during all days of the experiment (D4, D7, D9, D11, D14; *p* \< 0.001), resulting in an eradication of the implanted tumors in the absence of toxicity. The treated/control ratio (T/C) was \<10% and, according to the U.S. National Cancer Institute (NCI) rules, the drug combination is declared as very active \[[@B23-cancers-11-00775]\].

3. Discussion {#sec3-cancers-11-00775}
=============

PQR620 is a novel dual TORC1/2 inhibitor with higher affinity for the enzymatic catalytic domain than previously reported second-generation compounds, such as INK128, CC223 and AZD2014 \[[@B13-cancers-11-00775]\]. Here, we have shown that PQR620 had anti-tumor activity across 56 lymphoma models with a median IC~50~ value of 250 nM after 72 h of exposure, lower than what is reported in 66 cell lines derived from various solid tumors \[[@B13-cancers-11-00775]\].

PQR620 was largely cytostatic, as is the case for other mTOR inhibitors in lymphomas \[[@B24-cancers-11-00775],[@B25-cancers-11-00775],[@B26-cancers-11-00775]\]. However, when we combined the dual TORC1/TORC2 inhibitor with the BCL2 inhibitor venetoclax we observed an in vitro increase in cell death. Importantly, the benefit of the combination was validated in vivo upon treating xenografts derived from a GCB-DLBCL cell line with eradication of the tumor cells. Our data are in agreement with results obtained with venetoclax in combination with the other dual TORC1/TORC2, INK128, in acute myeloid leukemia \[[@B27-cancers-11-00775]\], as well as data reported in lymphoma models with the BCL2 inhibitor combined with the dual PI3K/mTOR inhibitor bimiralisib (PQR309) \[[@B28-cancers-11-00775]\] or different PI3K inhibitors \[[@B29-cancers-11-00775],[@B30-cancers-11-00775],[@B31-cancers-11-00775],[@B32-cancers-11-00775]\]. The effect appears to be mediated by downregulation of anti-apoptotic proteins (MCL1 or BCLXL) mediated by the inhibition of the PI3K/AKT/mTOR pathway \[[@B29-cancers-11-00775],[@B31-cancers-11-00775],[@B32-cancers-11-00775]\]. So far, in the clinical setting, the addition of venetoclax to other drugs seems feasible with no additional major toxicities \[[@B33-cancers-11-00775],[@B34-cancers-11-00775],[@B35-cancers-11-00775]\].

For novel compounds, it is useful to identify groups of patients that might benefit the most from the treatment. Genomics studies have identified DLBCL subgroups with a constitutively activated PI3K/mTOR pathway: GCB- and ABC-DLBCL, belonging to the B-cell receptor signaling cluster \[[@B36-cancers-11-00775]\], with GCB-DLBCL mostly falling into the newly described EZB subtype by Schmitz et al. \[[@B2-cancers-11-00775]\] or Cluster 3 by Chapuy et al. \[[@B1-cancers-11-00775]\]. Importantly, the available DLBCL cell lines recapitulate the genetic and biologic features of these clinical entities \[[@B32-cancers-11-00775],[@B36-cancers-11-00775]\], and PQR620 was active in such models. These classifications should be incorporated in the next clinical trials exploring PQR620 or other members of the same class to identify the patients that benefit the most from the treatment.

The anti-tumor activity of PQR620 was particularly high in the MCL cell lines. This observation is interesting, since MCL is the histotype in which first generation mTOR inhibitors have been mostly clinically developed \[[@B3-cancers-11-00775],[@B4-cancers-11-00775],[@B8-cancers-11-00775],[@B37-cancers-11-00775],[@B38-cancers-11-00775]\] with the European Medicines Agency (EMA) approval of temsirolimus for patients with relapsed/refractory disease \[[@B6-cancers-11-00775],[@B8-cancers-11-00775]\]. Additionally, although they could not be defined as resistant, two groups of lymphomas presented reduced sensitivity to PQR620. ALK+ALCL presented a lower sensitivity than the other cell lines. In this tumor, the PI3K/AKT/mTOR pathway is downstream of ALK and constitutively active \[[@B39-cancers-11-00775]\], but its inhibition alone might not be enough to efficiently target the lymphoma cells \[[@B40-cancers-11-00775],[@B41-cancers-11-00775]\].

The second group with decreased PQR620 sensitivity was represented by mutated DLBCL cell lines bearing an inactive *TP53*. The contribution of TP53 in the response to mTOR inhibitors is not defined, but it is certainly relevant in particular conditions \[[@B24-cancers-11-00775],[@B42-cancers-11-00775],[@B43-cancers-11-00775]\]. Data obtained in Eμ-Myc mouse lymphomas treated with everolimus clearly show that the lack of TP53 is a mechanism of primary resistance to the rapalog \[[@B24-cancers-11-00775]\], indicating the importance of a TP53-mediated component in the mechanism of action of this class of compounds in lymphomas. Referring again to the newly described DLBCL subtypes, patients belonging to Cluster 2 \[[@B1-cancers-11-00775]\], enriched in *TP53* mutations and deletions, do not represent the best target population for PQR620.

PQR620 was designed starting from the dual PI3K/mTOR inhibitor bimiralisib (PQR309) \[[@B44-cancers-11-00775],[@B45-cancers-11-00775]\], increasing the molecule affinity for mTOR while decreasing binding to PI3K \[[@B13-cancers-11-00775]\]. Bimiralisib has preclinical \[[@B28-cancers-11-00775]\] and early clinical anti-lymphoma activity \[[@B46-cancers-11-00775]\] in primary central nervous system lymphoma (PCNSL) \[[@B47-cancers-11-00775]\]. PQR620 retains the ability of bimiralisib \[[@B44-cancers-11-00775]\] to pass the blood-brain barrier \[[@B13-cancers-11-00775]\]. This is relevant as PQR620 was active in ABC DLBCL cell lines, and the most common type, PCNSL, which is an aggressive type of extranodal lymphoma, for which PI3K/mTOR inhibitors are an area of clinical research \[[@B48-cancers-11-00775]\]. Our data also show that PQ620 maintained the anti-tumor activity of bimiralisib reported in a canine DLBCL model \[[@B49-cancers-11-00775]\], indicating that dogs with spontaneous lymphomas might represent an effective pre-clinical animal model to test this compound as well.

4. Materials and Methods {#sec4-cancers-11-00775}
========================

4.1. In Vitro Experiments {#sec4dot1-cancers-11-00775}
-------------------------

Established human cell lines were cultured as previously described \[[@B28-cancers-11-00775]\] and their identity was authenticated by short tandem repeat (STR) DNA profiling (IDEXX BioResearch, Ludwigsburg, Germany). The status of *BCL2*, *MYC* and *TP53* was defined as previously reported \[[@B28-cancers-11-00775]\]. PQR620 was provided by PIQUR Therapeutics and dissolved in dimethyl sulphoxide (DMSO) to obtain a stock concentration of 10 mM. Venetoclax was obtained from Selleckchem (Houston, TX, USA). Viability and caspase-3/7 activation were assessed with the ApoTox-Glo Assay (Promega, Madison, WI, USA), as previously reported \[[@B21-cancers-11-00775]\]. Apoptosis was defined by at least a 1.5-fold increase in signal activation over controls \[[@B21-cancers-11-00775]\] and it was calculated in our models at the concentration of 1500 nM of PQR620. The effect on cell proliferation, cell cycle analysis and protein extraction, separation and immunoblotting were done as previously described \[[@B28-cancers-11-00775],[@B50-cancers-11-00775]\]. The following antibodies were used: AKT (CST 9272, Cell signaling Technology, Danvers, MA, USA), p-AKT (Ser 473) (CST 4060), p-p70 S6K (Thr 389) (CST 9205), p70 S6K (CST 9202), p-4e-BP1 (Thr 37/46) (CST 9459), 4e-BP1 (CST 9452) anti-GAPDH (Ebioscence FF26A). Associations in two-way tables were tested for statistical significance using either the *X*^2^ test or Fisher's exact test (two-tailed), as appropriate. Binomial exact 95% confidence intervals (95% C.I.s) were calculated for median percentages. Differences in IC~50~ values among lymphoma subtypes were calculated using the Wilcoxon rank-sum test. Statistical significance was defined by *p* values of 0.05 or less. The synergism of drug combination was calculated by using the Chou--Talalay Index, as previously done \[[@B28-cancers-11-00775]\]. Statistical analyses were performed using Stata/SE 12.1 for Mac (Stata Corporation, College Station, TX, USA), and boxplots with GraphPad Prism v. 7.0d (GraphPad Software, La Jolla, CA, USA).

4.2. In Vivo Experiments {#sec4dot2-cancers-11-00775}
------------------------

Xenograft experiments with the RI-1 and the SU-DHL-6 cell lines were performed using NOD-Scid (NOD.CB17-*Prkdcscid*/NCrHsd) mice and analysed as previously described \[[@B28-cancers-11-00775]\]. Mice maintenance and animal experiments were performed under the Guide of Animal Care and Use (NCR 2011) and under the Chinese National Standard (GB14925-2010) (Crown Bioscience Inc., Taicang City, China). These studies were part of two larger works assessing other agents; hence, the vehicle arm for the RI-1 xenograft and the vehicle and the venetoclax arms for the SU-DHL-6 xenograft have been previously reported \[[@B28-cancers-11-00775]\]. In vivo toxicity was evaluated by weighing the mice 3 times per week. Tumor weight loss higher than 10% in one week was considered to be the main sign of toxicity due to the drug. Treated/control ratio (T/C) was calculated at the end of the study as follows: T/C = (median tumor volume in the treated group/median tumor volume in the vehicle control group) × 100. A × T/C ≤ 42% was declared active in agreement with NCI criteria \[[@B23-cancers-11-00775]\].

5. Conclusions {#sec5-cancers-11-00775}
==============

In conclusion, PQR620 showed in vitro and in vivo anti-tumor activity in lymphoma models as a single agent and in combination with venetoclax, supporting its further development.

The following are available online at <https://www.mdpi.com/2072-6694/11/6/775/s1>. Figure S1: PQR620 was additive/synergistic when combined with venetoclax. Distribution of Chou-Talalay Combination Index (C.I.) values obtained in four DLBCL cell lines treated with different concentrations of PQR620 in combination with venetoclax. Y-axis, C.I. (C.I. \< 0.9, synergism; 0.9 \< C.I. \< 1.1, additive effect).
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Click here for additional data file.
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![PQR620 affects TORC1/2 signaling pathways by downregulating p-AKT, p-p70 S6 and p-4e-BP1 in most cell lines. Two ABC-DLBCL (TMD8, Ri-1) and three GCB-DLBCL (OCI-LY-1, SU-DHL-6, DoHH2) cell lines were treated with PQR620 (2 µM, 24 h) or, as control, DMSO.](cancers-11-00775-g001){#cancers-11-00775-f001}

![Effects of PQR620 as a single agent in a xenograft model of ABC-DLBCL. NOD-Scid mice subcutaneously inoculated with RI-1 (15 × 10^6^) cells were split into two groups respectively treated with PQR620 (50 mg/kg, 7 days/w, po, *n* = 8), and a control vehicle (*n* = 8). In each box-plot, the line in the middle of the box represents the median and the box extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., ±1.5 IQ). PQR620 versus vehicle, D2, D12, D14, D16, D19, D21, *p* \< 0.05.](cancers-11-00775-g002){#cancers-11-00775-f002}

![The combination of PQR620 and venetoclax are more in vitro cytotoxic than the single agents. Cell cycle distribution of four DLBCL cell lines (GCB: DOHH2, SU-DHL-6; ABC: TMD8, RI1) treated with two different concentrations of PQR620 (250 nM or 1 µM) and/or venetoclax.](cancers-11-00775-g003){#cancers-11-00775-f003}

![The combination of PQR620 and venetoclax have stronger in vivo anti-tumor activity than the single agents in a xenograft model of GCB-DLBCL. NOD-Scid mice subcutaneously inoculated with SU-DHL-6 (15 × 10^6^) cells were split into four groups respectively treated with PQR620 (100 mg/kg, Qdx7/w, po, *n* = 8), Venetoclax (100 mg/kg, Qdx7/w, a combination of PQR620 with venetoclax (*n* = 8) and control vehicle (*n* = 8). PQR620 versus vehicle, D4--D14, *p* \< 0.01; PQR620+venetoclax versus vehicle, D2--D14, *p* \< 0.01; PQR620+venetoclax versus PQR620, D2--D14, *p* \< 0.01; PQR620+venetoclax versus venetoclax, D2--D14, *p* \< 0.01. In each box-plot, the line in the middle of the box represents the median and the box extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., ±1.5 IQ).](cancers-11-00775-g004){#cancers-11-00775-f004}

cancers-11-00775-t001_Table 1

###### 

Anti-tumor activity of PQR620 in lymphoma cell lines. The IC~50~ was calculated after 72 h of drug exposure. Apoptosis was defined by at least a 1.5-fold increase in signal activation with respect to controls. *BCL2*, *MYC* and *TP53* status were defined as previously reported \[[@B21-cancers-11-00775]\].

  Cell Line          Histology      IC50 (nM)   Apoptosis Induction (At 1500 nM)   BCL2 Translocation   MYC Translocation   TP53 Inactive
  ------------------ -------------- ----------- ---------------------------------- -------------------- ------------------- ---------------
  **CLBL-1**         Canine DLBCL   267.38      no                                 n.a.                 n.a.                n.a.
  **DB**             GCB-DLBCL      507.79      no                                 1                    0                   
  **DOHH2**          GCB-DLBCL      144.03      no                                 1                    1                   0
  **ESKO-L**         MZL            378.09      no                                 n.a.                 0                   n.a.
  **FARAGE**         GCB-DLBCL      246.32      no                                 0                    0                   1
  **FE-PD**          PTCL-NOS       261.14      no                                 n.a.                 n.a.                n.a.
  **GRANTA519**      MCL            296.25      no                                 0                    0                   1
  **H9**             CTCL           614.19      no                                 n.a.                 n.a.                n.a.
  **HAIR-M**         MZL            332.6       no                                 n.a.                 0                   n.a.
  **HBL1**           ABC-DLBCL      370.8       no                                 n.a.                 0                   n.a.
  **HC1**            MZL            170.76      no                                 n.a.                 0                   n.a.
  **HH**             CTCL           128.83      no                                 n.a.                 n.a.                n.a.
  **HUT-78**         CTCL           1396.59     no                                 n.a.                 n.a.                n.a.
  **JEKO1**          MCL            234.54      no                                 0                    0                   1
  **JVM2**           MCL            131.66      no                                 0                    0                   0
  **KARPAS1106-P**   PMBCL          322.89      yes                                n.a.                 0                   n.a.
  **KARPAS1718**     MZL            735.31      no                                 n.a.                 0                   1
  **KARPAS299**      ALCL, ALK+     425.69      no                                 n.a.                 n.a.                1
  **KARPAS422**      GCB-DLBCL      150.77      no                                 1                    0                   1
  **KI-JK**          ALCL, ALK+     456.52      no                                 n.a.                 n.a.                n.a.
  **L82**            ALCL, ALK+     364.12      no                                 n.a.                 n.a.                1
  **MAC1**           ALCL, ALK−     233.13      no                                 n.a.                 n.a.                n.a.
  **MAVER1**         MCL            91.78       no                                 n.a.                 1                   1
  **MEC1**           CLL            348.52      no                                 n.a.                 0                   1
  **MINO**           MCL            120.78      no                                 n.a.                 1                   1
  **OCI-LY-1**       GCB-DLBCL      314.96      no                                 1                    0                   1
  **OCI-LY-10**      ABC-DLBCL      220.15      no                                 0                    0                   1
  **OCI-LY-18**      GCB-DLBCL      285.09      no                                 1                    1                   1
  **OCI-LY-19**      GCB-DLBCL      128.81      no                                 1                    n.a.                0
  **OCI-LY-3**       ABC-DLBCL      127.2       no                                 0                    0                   0
  **OCI-LY-7**       GCB-DLBCL      107.01      no                                 0                    1                   1
  **OCI-LY-8**       GCB-DLBCL      210.4       no                                 1                    1                   1
  **PCL12**          CLL            109.21      no                                 n.a.                 0                   n.a.
  **PFEIFFER**       GCB-DLBCL      1069.2      no                                 1                    0                   1
  **RCK8**           GCB-DLBCL      5.05        yes                                n.a.                 0                   0
  **REC1**           MCL            80.53       no                                 n.a.                 0                   1
  **RI-1**           ABC-DLBCL      346.24      no                                 n.a.                 1                   1
  **SP49**           MCL            250         yes                                n.a.                 0                   n.a.
  **SP53**           MCL            149.61      no                                 n.a.                 0                   n.a.
  **SSK41**          MZL            200.25      no                                 n.a.                 0                   n.a.
  **SU-DHL-1**       ALCL, ALK+     670.6       yes                                n.a.                 n.a.                1
  **SU-DHL-10**      GCB-DLBCL      186.81      no                                 1                    1                   1
  **SU-DHL-16**      GCB-DLBCL      249.06      no                                 n.a.                 n.a.                n.a.
  **SU-DHL-2**       ABC-DLBCL      320.52      no                                 0                    0                   n.a.
  **SU-DHL-4**       GCB-DLBCL      226.36      no                                 1                    0                   1
  **SU-DHL-5**       GCB-DLBCL      166.23      yes                                0                    0                   n.a.
  **SU-DHL-6**       GCB-DLBCL      398.97      no                                 1                    0                   1
  **SU-DHL-8**       GCB-DLBCL      396.7       no                                 0                    1                   n.a.
  **TMD8**           ABC-DLBCL      161.29      yes                                n.a.                 0                   0
  **TOLEDO**         GCB-DLBCL      349.22      yes                                1                    1                   1
  **U2932**          ABC-DLBCL      239.77      yes                                0                    0                   1
  **UPN1**           MCL            253.94      no                                 n.a.                 0                   1
  **VAL**            GCB-DLBCL      261.31      no                                 1                    1                   0
  **VL51**           MZL            215.97      no                                 n.a.                 0                   n.a.
  **WSU-DLCL2**      GCB-DLBCL      264.18      no                                 1                    0                   1
  **Z138**           MCL            237.47      no                                 n.a.                 1                   n.a.

DLBCL, diffuse large B-cell lymphoma; ABC-DLBCL, activated B-cell like diffuse large B-cell lymphoma; GCB-DLBCL, germinal center B-cell type diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; ALCL, ALK+, ALK positive anaplastic large cell lymphoma; MZL, marginal zone lymphoma; CTCL, cutaneous T cell lymphoma; CLL, chronic B-cell leukemia; cALCL, cutaneous anaplastic large cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; PTCL-NOS, peripheral T cell lymphoma, not otherwise specified; n.a. not available.

cancers-11-00775-t002_Table 2

###### 

Anti-tumor activity of PQR620 based on histology.

  Histology       Median IC~50~ (nM)   95% Conf. Interval   Number of Cell Lines
  --------------- -------------------- -------------------- ----------------------
  ABC-DLBCL       230                  88--354              8
  GCB-DLBCL       249                  181--325             19
  Canine DLBCL    267                  n.d.                 1
  MCL             192                  101--253             10
  MZL             274                  174--700             6
  PMBCL           323                  n.d.                 1
  CLL             229                  109--349 \*          2
  ALCL, ALK+      441                  364--671 \*          4
  CTCL            614                  129--1370 \*         3
  PTCL-NOS        261                  n.d.                 1
  cALCL, ALKneg   233                  n.d.                 1

DLBCL, diffuse large B-cell lymphoma; ABC-DLBCL, activated B-cell like diffuse large B-cell lymphoma; GCB-DLBCL, germinal center B-cell type diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; ALCL, ALK+, ALK positive anaplastic large cell lymphoma; MZL, marginal zone lymphoma; CTCL, cutaneous T cell lymphoma; CLL, chronic B-cell leukemia; cALCL, cutaneous anaplastic large cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; PTCL-NOS, peripheral T cell lymphoma, not otherwise specified. \* Lower confidence limit held at minimum (maximum) of sample \[[@B22-cancers-11-00775]\]. n.d., not determined.
